SOL stock

SOL · Borsa Italiana · EUR

Compare SOL
€64.60Change from previous close: −2.27%Absolute change: −€1.50

Close · November 17, 2026

Price history

+38.16% over the period

1 year: from €47.70 (November 17, 2025) to €65.90 (November 17, 2026), +38.16%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026€65.90
October 30, 2026€59.80
September 30, 2026€56.50
August 31, 2026€56.30
July 31, 2026€56.90
June 30, 2026€58.20
May 29, 2026€56.50
April 30, 2026€57.60
March 31, 2026€58.90
February 27, 2026€51.60
January 30, 2026€45.40
December 30, 2025€48.95
November 28, 2025€49.85
November 17, 2025€47.70

At a glance

  • The company

    Produces and distributes technical and medical gases, healthcare services, and advanced biomedical solutions for industrial and healthcare sectors

  • Latest results

    Quarter to June 30, 2026 · EPS €0.99

TickerLandia's take on SOL

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€44.85
52-wk high€66.20

−2.42% from the 52-week high

Analysts · 4 analysts

Average target€66.88+3.52% vs. price

Buy 4 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: SOL

Compared with similar companies: very strong momentum.

Financials and price compared with 59 companies in the specialty chemicals industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

SOL is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), SOL's P/E today is 35.8, above the median of its last 10 fiscal years (18.6; between 12.0 and 26.6 from 2016 to 2025). SOL's P/E (trailing 12 months): 34.6, +28% against the median of a group of 9 similar companies (27.1).

P/E compared with its history

Compared with 9 similar companies

SOL's metrics compared with similar companies
MetricSOLPosition in the groupBand
P/E (trailing 12 months)34.6Middle
Forward P/E28.5High
Operating margin15.1%High
ROE15.6%High
Debt/equity0.71Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: SOL. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€962.69M

Latest quarter · Q2 2026

Net income

€89.87M

Latest quarter · Q2 2026

Quarterly net margin

9.3%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€5.99B
P/E
34.6
EPS
€1.91
Volume
77.86K
Daily trading
€2.61M
Dividend yield
0.70%
Last ex-dividend on May 18, 2026

How SOL is changing

All results
  • Revenue grew 13.1% a year on average over the last 5 years

  • Operating margin rose from 11.0% to 14.9%

  • Free cash flow equal to 61% of net income

Returns

SOL returns with dividends

€1,000 invested in SOL 5 years ago, on November 17, 2021, would be worth €3,200 today with dividends reinvested: +220.05% in total, +26.20% per year. On price alone it would be €3,030 (+202.99%).

PeriodSOLFTSE MIB€1,000 becomes
1 month+17.68%+3.59%€1,177
6 months+9.31%+3.52%€1,093
Year to date+34.63%+13.13%€1,346
1 year+39.21%+16.17%€1,392
3 years+146.47%+72.37%€2,465
5 years+220.05%+82.73%€3,200
10 years+938.36%+207.13%€10,384

Over the last 6 months it has done better than 77% of the stocks in the Materials sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment

The chart in detail

SOL: technical analysis

SOL is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 2.3% below its all-time closing high (€66.10, November 16, 2026).

Trend
Upward
RSI (14 sessions)
65
Between 30 and 70
vs 200-session average
+14.19%

Support and resistance

Price areas where SOL has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€64.60
  3. Support€63.80−1.24%2 touches, last on July 27, 2026
  4. Support€60.90−5.73%3 touches, last on July 7, 2026
  5. Support€59.30−8.20%3 touches, last on October 6, 2026

Volatility and risk

Over the last year it has moved little with the FTSE MIB.

Beta (1 year) vs FTSE MIB
0.39
Volatility (60 sessions, annualised)
30.9%
Largest fall in the last year
−17.19%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

SOL: seasonality

Average monthly price change over 29 years

+1.4%Jan+2.2%Feb+3.2%Mar+2.6%Apr+2.7%May+0.2%Jun+1.3%Jul+0.2%Aug−1.2%Sep+0.1%Oct+0.2%Nov+0.3%Dec

Over the last 29 years, the strongest month for SOL has been March: +3.18% on average, positive in 17 years out of 28. The weakest has been September: −1.25% on average, positive in 10 years out of 29. November, the current month, has been positive in 14 years out of 28 (+0.16% on average).

Show chart data
MonthAverageMedianPositive years
January+1.45%+3.35%17 of 28
February+2.20%+1.25%15 of 28
March+3.18%+2.17%17 of 28
April+2.60%+3.05%19 of 28
May+2.73%+2.56%17 of 28
June+0.16%−0.82%13 of 28
July+1.33%+1.63%15 of 28
August+0.20%+0.93%15 of 29
September−1.25%−1.24%10 of 29
October+0.06%+1.49%17 of 29
November+0.16%0.00%14 of 28
December+0.26%+0.28%15 of 28

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

SOL and its competitors

Its sales reach Italian and foreign markets, where it supplies gases, equipment and services to factories as well as to hospitals and care providers. Industrial offerings span oxygen, nitrogen, argon, hydrogen, carbon dioxide and liquefied natural gas, alongside high purity and electronics gases. The healthcare arm covers medical gases, respiratory and infusion therapies, hospital hygiene, telemedicine and digital services. Specialised units add CRYOLAB, which handles biological samples, DIATHEVA, which develops monoclonal antibodies and molecular kits, and PERSONAL GENOMICS for precision medicine.

Headquarters
Monza, Italy
Employees
8,000
Founded
1927
SOL and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
SOLSOL$6.58B15.1%34.6+9.31%
Croda InternationalCRDA$6.81B7.3%64.4+36.74%
IMCDIMCD$6.83B8.1%27.1+9.61%
FUCHSFPE$5.91B13.1%17.2+26.11%
ArkemaAKE$4.94B4.6%234.8−7.82%
Wacker ChemieWCH$4.41B5.1%—−19.15%

Same industry or related industries, similar size. Compare SOL with its competitors · Full profile